Court May Ask Roche To Pay Amgen 22.5 Percent Royalty To Market Mircera
Executive Summary
A district court judge issued a preliminary injunction blocking Roche's launch of Mircera (epoetin beta) in the United States and suggested the terms under which Roche might begin selling its anti-anemia drug
You may also be interested in...
As Amgen Drops Some ESA “Overhangs,” New Payment Threat Appears
Amgen could be facing a new threat on the reimbursement front just days after celebrating the removal of several "major overhangs" to its erythropoiesis-stimulating agents during its second quarter earnings call
As Amgen Drops Some ESA “Overhangs,” New Payment Threat Appears
Amgen could be facing a new threat on the reimbursement front just days after celebrating the removal of several "major overhangs" to its erythropoiesis-stimulating agents during its second quarter earnings call
Amgen v. Roche: Mircera Battle Continues In Court And At Trade Commission
Roche has agreed to the conditions set by a federal judge for the launch of its anti-anemia drug Mircera (epoetin beta) in the U.S